We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A
BIO

490 hedge funds and large institutions have $11.5B invested in Bio-Rad Laboratories Class A in 2020 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 177 increasing their positions, 176 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

33% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 57

16% more capital invested

Capital invested by funds: $9.85B → $11.5B (+$1.61B)

3% more funds holding

Funds holding: 478 → 490 (+12)

1.14% more ownership

Funds ownership: 78.38% → 79.52% (+1.1%)

1% more repeat investments, than reductions

Existing positions increased: 177 | Existing positions reduced: 176

8% less call options, than puts

Call options by funds: $14.7M | Put options by funds: $16M

Holders
490
Holders Change
+12
Holders Change %
+2.51%
% of All Funds
8.67%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.12%
New
76
Increased
177
Reduced
176
Closed
57
Calls
$14.7M
Puts
$16M
Net Calls
-$1.25M
Net Calls Change
+$4.17M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$164M
2
BlackRock
BlackRock
New York
+$154M
3
HM
HealthCor Management
New York
+$79.8M
4
California Public Employees Retirement System
California Public Employees Retirement System
California
+$72.4M
5
UBS AM
UBS AM
Illinois
+$66.9M

Top Sellers

1
GQG Partners
GQG Partners
Florida
-$183M
2
American Century Companies
American Century Companies
Missouri
-$102M
3
ACM
Atlanta Capital Management
Georgia
-$89.1M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$48.1M
5
Wells Fargo
Wells Fargo
California
-$42.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
EIP
251
Easterly Investment Partners
Massachusetts
$1.07M -$808K -1,418 -44%
ACM
252
AlphaCrest Capital Management
New York
$1.07M +$1.05M +1,841 New
NB
253
Norinchukin Bank
Japan
$1.03M -$17.1K -30 -2%
PP
254
Paloma Partners
Connecticut
$1.02M +$665K +1,168 +198%
Bessemer Group
255
Bessemer Group
New Jersey
$992K +$402K +706 +71%
LIM
256
Leavell Investment Management
Alabama
$991K – – –
TPCW
257
TD Private Client Wealth
New York
$982K -$136K -239 -12%
SLAM
258
Swiss Life Asset Management
$978K -$32.5K -57 -3%
P
259
Pitcairn
Pennsylvania
$976K +$86K +151 +10%
GAM
260
Gotham Asset Management
New York
$961K -$353K -620 -27%
HighTower Advisors
261
HighTower Advisors
Illinois
$956K -$173K -304 -15%
HF
262
HRT Financial
New York
$935K +$913K +1,604 New
HC
263
Henshaw Capital
Massachusetts
$928K -$413K -726 -31%
MYAM
264
Meiji Yasuda Asset Management
Japan
$909K +$888K +1,560 New
AWM
265
Avior Wealth Management
Nebraska
$887K -$1.14K -2 -0.1%
PAS
266
Park Avenue Securities
New York
$883K +$69.5K +122 +9%
ICM
267
Intrepid Capital Management
Florida
$881K -$100K -176 -10%
AO
268
Advisor OS
Illinois
$878K +$191K +336 +29%
CAM
269
Crown Advisors Management
California
$874K – – –
WAM
270
Westport Asset Management
Connecticut
$874K – – –
AIL
271
AGF Investments LLC
Ontario, Canada
$869K -$1.23M -2,167 -59%
RWM
272
Ritholtz Wealth Management
New York
$868K +$66.6K +117 +9%
Wealthfront Advisers
273
Wealthfront Advisers
California
$865K +$188K +330 +29%
IG
274
ING Group
Netherlands
$832K +$544K +955 +202%
Pacer Advisors
275
Pacer Advisors
Pennsylvania
$823K -$630K -1,106 -44%
9 10
11
12 13

BIO Hedge Fund Activity: Q4 2020 in Review

490 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2020, worth a combined $11.5B — up 16% from $9.85B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new BIO positions and 57 closed out — a net gain of 19 holders — while 177 added to existing stakes and 176 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $164M. The largest seller was GQG Partners, exiting entirely with an estimated $183M sold.

  • 490 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2020, up from 478 in Q3 2020.
  • Funds reported $11.5B of Bio-Rad Laboratories Class A stock for Q4 2020, up 16% quarter-over-quarter.
  • 76 funds opened new Bio-Rad Laboratories Class A positions in Q4 2020 and 57 closed out, a net change of +19 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q4 2020 was Fidelity Investments, an estimated $164M added.
  • The largest Bio-Rad Laboratories Class A seller in Q4 2020 was GQG Partners, an estimated $183M sold.

Based on aggregated 13F filings for Q4 2020.